Skip to content
Results
Menu
Contact Us
Careers
MyASHM
Join ASHM
Search
Close
Join ASHM
Contact Us
Careers
MyASHM
Menu
Contact Us
Careers
MyASHM
Home
Acknowledgements
Feedback
Menu
Home
Acknowledgements
Feedback
Results
Home
Acknowledgements
Feedback
Menu
Home
Acknowledgements
Feedback
Post-Exposure Prophylaxis after non-occupational and occupational exposure to HIV
Australian National Guidelines (Third Edition)
Download Guidelines
Last Updated: June 2023
PEP Guidelines: Quick-Reference
Immediate Management and Assessment
Immediate management of a person with known or suspected exposure to HIV
Clinical Assessment
Assessment of Risk
Estimated risk of HIV transmission by exposure
What is the HIV status of the source individual?
Prescribing PEP
When to Prescribe PEP
Prescribing PEP
Recommended PEP Regimens
ARV Agents not recommended for PEP
Side-effects of recommended PEP medications
Drug-Drug Interactions
Laboratory Testing for HIV PEP recipients
Exposure to Other Conditions
Hepatitis B virus
STIs
Hepatitis C virus
Pregnancy and Lactation
Tetanus
Specific Clinical Situations for PEP
People who miss a PEP dose
People at risk of HIV acquisition who decline PEP
People at negligible risk of HIV transmission who request PEP
People who re-present for PEP after completion of a PEP course
People who re-present with additional high-risk exposure(s) while taking a PEP course
People who are on PrEP
People who are transitioning from PEP to PrEP
PEP in Specific Populations
Trans and Gender Diverse People
Adult sexual assault (> 16 years of age)
Children (younger than 16 years of age)
People living in correctional or detention facilities
People who commenced PEP overseas
Further Information
List of Tables and Figures
Glossary
Phone support for clinicians
Information for patients
Appendix A: Estimated HIV acquisition risk if source is viraemic, by population group
Appendix B: Evidence for three-drug versus two-drug PEP regimens
Appendix C: Cost of PEP regimens
Appendix D: Methods
References
Menu
PEP Guidelines: Quick-Reference
Immediate Management and Assessment
Immediate management of a person with known or suspected exposure to HIV
Clinical Assessment
Assessment of Risk
Estimated risk of HIV transmission by exposure
What is the HIV status of the source individual?
Prescribing PEP
When to Prescribe PEP
Prescribing PEP
Recommended PEP Regimens
ARV Agents not recommended for PEP
Side-effects of recommended PEP medications
Drug-Drug Interactions
Laboratory Testing for HIV PEP recipients
Exposure to Other Conditions
Hepatitis B virus
STIs
Hepatitis C virus
Pregnancy and Lactation
Tetanus
Specific Clinical Situations for PEP
People who miss a PEP dose
People at risk of HIV acquisition who decline PEP
People at negligible risk of HIV transmission who request PEP
People who re-present for PEP after completion of a PEP course
People who re-present with additional high-risk exposure(s) while taking a PEP course
People who are on PrEP
People who are transitioning from PEP to PrEP
PEP in Specific Populations
Trans and Gender Diverse People
Adult sexual assault (> 16 years of age)
Children (younger than 16 years of age)
People living in correctional or detention facilities
People who commenced PEP overseas
Further Information
List of Tables and Figures
Glossary
Phone support for clinicians
Information for patients
Appendix A: Estimated HIV acquisition risk if source is viraemic, by population group
Appendix B: Evidence for three-drug versus two-drug PEP regimens
Appendix C: Cost of PEP regimens
Appendix D: Methods
References
Contact us
Name
Email
Message
Send
Scroll to Top